Merus Advances Petosemtamab to Phase 3 as Licensing Deals Expand Global Reach

Introduction

Merus B V (NASDAQ: MRUS) is a clinical-stage biotechnology company headquartered in Utrecht, Netherlands, with a U.S. subsidiary in Cambridge, Massachusetts. Founded in 2006, Merus utilizes its proprietary Multiclonics® platform to develop full-length human bispecific and trispecific antibodies that aim to engage the immune system to target cancer cells.

Corporate Structure

Merus employs between 201 and 500 professionals, including research scientists, clinical development experts, and corporate support teams. With facilities in Europe and North America, the company emphasizes equality and diversity, fostering collaboration across discovery, manufacturing, and clinical operations.

Biotechnology by Louis Reed

Developments and News

On November 1, 2025, Merus announced that petosemtamab (MCLA-158) had entered phase 3 trials for recurrent or metastatic head and neck cancer. In September 2025, Merus granted Partner Therapeutics exclusive U.S. commercialization rights for BIZENGRI® (NRG1 fusion-positive cancers). A licensing agreement with Betta Pharmaceuticals in July 2025 provided development and commercialization rights in Greater China for MCLA-129, an EGFR/c-MET bispecific candidate. In Schedule 13G/A amendments filed on November 14, 2025, Paradigm BioCapital Advisors reported beneficial ownership of 6.2%, RTW Investments reported 2.7%, and Wellington Management Group reported 0.6%.

Financial and Strategic Analysis

As of November 26, 2025, MRUS shares traded at $96.10, reflecting a change of 0.08%, on a volume of 213,409 shares. The company’s market capitalization was approximately $7.26 billion, with an enterprise value of $6.64 billion. For the trailing twelve months, revenue was $56.61 million against net losses of $381.14 million (TTM EPS: –$5.28). Cash and equivalents amounted to $635.93 million at the end of the latest quarter, and total debt represented 1.59% of equity. The price/sales ratio was 120.26, and the EV/revenue multiple was 117.29.

Market Position and Industry Context

Merus operates within the immuno-oncology sector alongside other developers of bispecific antibodies. Its Multiclonics® technology enables simultaneous targeting of multiple tumor antigens in a full-length IgG format. Lead programs address high-unmet-need indications, including head and neck cancer and NRG1 fusion-positive tumors. The broader oncology antibody market benefits from regulatory incentives such as Breakthrough Therapy designations and increased demand for targeted treatments. Merus’s strategic partnerships and retained global rights (excluding China for MCLA-129) support its commercial reach and control over key assets.

tl;dr

Petosemtamab advanced to phase 3 head and neck cancer trials on November 1, 2025. Licensing agreements with Partner Therapeutics (U.S.) and Betta Pharmaceuticals (Greater China) expand Merus's commercial reach. As of November 26, 2025, MRUS traded at $96.10, reflecting a market capitalization of $7.26 billion, $56.6 million in revenue, and a net loss of $381 million. Upcoming catalysts include phase 3 data readouts, additional licensing transactions, and potential FDA approvals.